Please ensure Javascript is enabled for purposes of website accessibility

Why Axsome Therapeutics Stock Rose Today

By Prosper Junior Bakiny - Aug 10, 2020 at 3:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.

What happened?

Shares of Axsome Therapeutics (AXSM 2.10%) -- a clinical-stage biotech -- rose sharply on Monday and closed the day's trading session up by 4.8%, following the company's release of its second-quarter financial results. The most important part of Axsome's quarterly update was encouraging news regarding two of its leading pipeline candidates.

So what

Axsome's AXS-05 is a potential treatment for several conditions, including major depressive disorder (MDD) and Alzheimer's disease (AD). The company is gearing up to submit AXS-05 to the U.S. Food and Drug Administration (FDA) for the treatment of MDD, and management thinks it will be able to do so in the fourth quarter of 2020. Note that the FDA granted AXS-05 the breakthrough therapy and fast track designations for the treatment of MDD. Also, Axsome is on track to submit AXS-07, a drug for the acute treatment of migraine, in the fourth quarter.

Man standing on a ladder drawing an upward pointing graph on a board.

Image source: Getty Images.

Now what

Axsome currently has no products on the market. During the second quarter, the company did not generate a single dollar in revenue and reported a net loss per share of $0.49. However, the approval of AXS-05 and AXS-07 -- which could happen sometime next year -- would allow the company's financial results to improve significantly.

The biotech estimates that AXS-05 could bring in peak sales between $1 billion and $2 billion annually for the treatment of MDD. Meanwhile, the company's AXS-07 could generate between $500 million and $1 billion in sales every year. It will likely be about a year before Axsome launches these products on the market, but given these exciting opportunities, it is not surprising that investors bid up shares of the company following its quarterly update.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
$46.27 (2.10%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.